Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $63.07 USD
Change Today -1.70 / -2.62%
Volume 1.1M
ALKS On Other Exchanges
Symbol
Exchange
NASDAQ GS
As of 8:10 PM 07/2/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

Connaught House

1 Burlington Road

Dublin, 4

Ireland

Phone: 353 1 772 8000

Fax:

the natural mechanism of action of a biologic product. The company expects to initiate clinical development of RDB 1419 in 2015. Partnered Product Candidates—Development Programs Acorda In December 2014, Acorda announced the initiation of a phase 3 clinical trial of dalfampridine extended release tablets for the treatment of post-stroke walking deficits. It expects this multicenter, double-blind, randomized trial to enroll approximately 540 participants who have experienced an ischemic stroke approximately six months prior to enrollment. Janssen In July 2014, Janssen announced the submission of a supplemental NDA to the FDA seeking a label change that, if approved, is expected to include new data showing delayed time to relapse in patients prescribed INVEGA SUSTENNA, as compared to selected oral antipsychotic therapies, in the treatment of schizophrenia. In November 2014, Janssen announced the submission of an NDA to the FDA for three-month atypical antipsychotic paliperidone palmitate for the treatment of schizophrenia in adults. If approved, it would be the first and only long-acting atypical antipsychotic that has a four times a year dosing schedule. AstraZeneca AstraZeneca is developing line extensions for BYDUREON for the treatment of type 2 diabetes, including weekly and monthly suspension formulations using the company’s proprietary technology for extended-release microspheres. In 2014, AstraZeneca announced the completion of two phase 3 trials of exenatide once weekly suspension for autoinjection, DURATION-NEO-1 and DURATION-NEO-2. The DURATION-NEO-1 phase 3 study evaluated exenatide once weekly suspension for autoinjection compared to twice-daily exenatide in adult patients with type 2 diabetes that had inadequate glycemic control. The trial met its primary endpoint of non-inferiority. The DURATION-NEO-2 study was a randomized, long-term, open-label, multicenter study comparing the glycemic effects, safety and tolerability of exenatide once weekly suspension to sitagliptin and placebo in subjects with type 2 diabetes. AstraZeneca expects to file marketing applications for this product candidate in the U.S. and EU in 2015. Agreements The company has an asset purchase and license agreement and equity investment agreement with Civitas Therapeutics, Inc. Marketing, Sales and Distribution The company is responsible for marketing VIVITROL in the U.S. The company focuses its sales and marketing efforts on specialist physicians in private practice and in public treatment systems. The company provides, or contracts with third-party vendors to provide, customer service and other related programs for its product, such as product-specific Websites, insurance research services and order, delivery and fulfillment services. The company’s sales force for VIVITROL in the U.S. consists of approximately 70 individuals. VIVITROL is sold directly to pharmaceutical wholesalers, specialty pharmacies, and a specialty distributor. Product sales of VIVITROL to CVS Caremark Corporation and McKesson Corporation represented approximately 17% and 15%, respectively, of total VIVITROL sales during the year ended December 31, 2014. Cardinal Health Specialty Pharmaceutical Services, a division of Cardinal Health Inc., provides warehousing, shipping and administrative services for VIVITROL. Patents and Proprietary Rights The company owns approximately 200 issued U.S. patents. The latest of the patents covering AMPYRA/FAMPYRA expires in 2027 in the U.S. and 2025 in Europe. The company also has various pending patent applications covering its NanoCrystal technology. The latest of the patents covering INVEGA SUSTENNA expires in 2019 in the U.S. and 2022 in the EU. Additional pending applications might provide a longer period of patent coverage, if granted, and in certain countries, such as Australia and South Korea, patent coverage extends until 2023. The company has filed patent applications worldwide that cover its microsphere technology and has various patents and pending patent applications covering its microsphere technology. The latest of its patents covering VIVITROL, RISPERDAL CONSTA and B

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALKS:US $63.07 USD -1.70

ALKS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cosmo Pharmaceuticals SA SFr.169.90 CHF -1.30
Emergent BioSolutions Inc $32.36 USD -0.96
Impax Laboratories Inc $46.31 USD -0.34
Jazz Pharmaceuticals PLC $177.37 USD +0.24
Pacira Pharmaceuticals Inc/DE $69.54 USD -0.46
View Industry Companies
 

Industry Analysis

ALKS

Industry Average

Valuation ALKS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 14.4x
Price/Book 6.6x
Price/Cash Flow 383.7x
TEV/Sales 12.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALKERMES PLC, please visit www.alkermes.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.